This report describes a one-pot process for
the preparation of acyclovir from guanine.
Reacting N2,N9-diprotected guanine with 1-
acetyl-2-acetylmethoxy-ethyleneglycol in
present of phosphoric acid as catalyst provide
ACV with high yield and good regioselectivity.
Therefore, the purification was simple,
inexpensive and conforming to pilot scale. The
chemicals and the solvents were common and
friendly with environment. The antiherpetic
activity of the synthesized ACV was show to be
comparable (95%) to the standard ACV. This
synthesized ACV was approved by National
Institute of Drug Quality Control to meet the
quality standard of BP 2007.
6 trang |
Chia sẻ: honghp95 | Lượt xem: 651 | Lượt tải: 0
Bạn đang xem nội dung tài liệu Synthesis of acyclovir as an antiherpes-Virus drug - Trần Quang Hưng, để tải tài liệu về máy bạn click vào nút DOWNLOAD ở trên
523
Journal of Chemistry, Vol. 47 (4), P. 523 - 528, 2009
SYNTHESIS OF ACYCLOVIR AS AN ANTIHERPES-VIRUS DRUG
Received 4 February 2009
Tran Quang Hung1, Nguyen Thi Thuong2, Tran Van Sung1
1Laboratory of Organic Synthesis, Institute of Chemistry, VAST
2Laboratory of Herpes viruses, Faculty of Virus, National Institute of Hygiene and Epidemiology
Abstract
A one-pot process for high-yield regioselective synthesis of 9-[(2-hydroxyethoxy)
methyl]guanine (acyclovir), an antiherpetic agent, was achieved from guanine via the steps of
reacting of N2,N9 -diprotected guanine with 1-acetyl-2-acetylmethoxy-ethyleneglycol in presence
of phosphoric acid or polyphosphoric acid. Total yield of product was 59%. The obtained
acyclovir meets the standards in the British Pharmacopoeia 2007 (BP2007). Its activity as
inhibitor of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) was evaluated according to
the plaque reduction assay method and compared with the standard compound. The synthesized
acyclovir showed a similar activity as the control.
Keywords: Acyclovir, Herpes simplex virus, Nucleoside, One- pot synthesis.
I - Introduction
Virus was a cause of many dangerous
diseases and variety of epidemic diseases in
large area. It is important that antibiotics have
no or almost no effect on viruses. Although the
production of herpes vaccine is desired by many
countries but it still stays on a testing level. The
prevention of herpes infection is a special
problem because the disease often recurred in
present of antibody. Therefore, development of
anti-virus drugs is important, necessary and still
be a leading interest.
1: Acyclovir
Acyclovir, {9-[(2-hydroxyethoxy)methyl]
guanine} (ACV 1), was first reported by
Schaeffer and co-workers [1] and is a nucleoside
analogue. It acts selectively on herpes-infected
cells. It has specific inhibition effects on
replication of herpes virus simplex type 1 and
type 2 (HSV1 and HSV2) and Varicella zoster
virus that cause almost no intoxication to the
host cells. From nearly three decades ago, ACV
was used as a primary drug to treat herpes virus,
especially genital herpes and herpes simplex
encephalitis and herpes in immunity deficient
people [2].
ACV has no activity against viral pathogens
until it is converted to an active form acyclovir
triphosphate. Its mechanism of action is initiated
by the viral enzyme Thymidine kinase;
subsequently, human Cellular kinase perform
the second and the third phosphorylation steps
to complete the process (figure 1). Acyclovir
triphosphate, the active form of acyclovir, is
present in 40- to 100-fold higher concentrations
in herpes simplex virus (HSV)-infected cells
than in uninfected cells. As a result, the
selectivity of ACV is significant [3, 4].
524
Acyclovir triphosphate has a two-pronged
mechanism of action: (1) it competes with 2-
deoxyguanosine triphosphate (dGTP) as a
substrate for viral DNA polymerase and (2)
once it becomes incorporated into the
replicating viral DNA, it acts as a chain
terminator because it does not have a terminal
3-hydroxyl group [3].
Figure 1: Acyclovir mechanism of action
ACV was prepared in different forms such
as tablets (200 mg, 400 mg, 800 mg), capsules
200 mg, powder for injection, oral suspension,
creams for skin 5% and for eyes 3%. After oral
administration, ACV is absorbed slowly and not
completely, bioavailability of only 10-20% [9].
ACV rapidly attracted attention of chemist,
as well as pharmacist by virtue of its selective
anti-virus activity and effect. There were many
efforts for synthesis of ACV by different ways
reported. Among divert orientations of
synthesizing ACV, it could be accounted 5
common and most effective pathways. The most
common pathway departed from guanine with
effectiveness and simplicity where guanine was
acylated [5]. The important problem is to
decrease the N7 substituted isomer and
selectively akylating into N9 position. Our
synthesis of ACV is showed in figure 2.
Figure 2: Pathway for synthesis of acyclovir
II - Experimental
Preparation of dioxolane-diacetate (1-acetyl-
2-acetylmethoxy-ethyleneglycol)
Dioxolane 5 (224 g, 99%, 211.6 ml, 3 mol)
was added drop wise to a solution of p-
toluenesulfonic acid monohydrate (10 g, 0.053
mol) in acetic anhydride (306 g, 283.3 ml,3
mol) and acetic acid (45 g, 42.9 ml, 0.75 mol)
precooled to below 10oC, at the rate that
maintained the reaction temperature under 30oC.
The solution was then stirred for an additional
hour at a temperature under 30oC, and then
distilled. The first portion of distillate was
collected at a temperature of 40 - 80oC/1.5
mmHg and contained acetic acid, acetic
anhydride, and other materials. The second
portion of distillate was collected at 80 - 95oC.
at 0.75 mmHg and redistilled to give pure 7 in a
yield of 431.5 g (81.7%). 1H-NMR (CD3OD,
500 MHz, δ ppm): 2.06, 2.08 (s, 6H, 2xCH3),
3.85, 4.21 (s, 4H, OCH2CH2O), 5.28 (s, 2H,
OCH2O).
525
Figure 3: Preparation of Dioxolane-diacetate
Preparation of acyclovir
A mixture of guanine (3, 32.13 g, 213
mmol), acetic anhydride (320 ml) and acetic
acid (480 ml) was refluxed overnight, during
which time the mixture became almost clear.
The liquid was removed by evaporation in
reduced pressure. To the residue was added
toluene (300 ml), 7 (75 g, 426 mmol), and
phosphoric acid (85.5%, 1.5 ml) with stirring.
The resulting mixture was refluxed for 6 - 7
hours with vigorous stirring.
Toluene and acetic anhydride were then
removed under reduced pressure and the residue
was heated at 80oC (oil bath) under reduced
pressure (20 mm Hg) for another 2 hours,
cooled to room temperature, triturated with
ethyl acetate (100 ml), and stirred at room
temperature overnight.
The resulting solid was collected by
filtration, washed twice with ethyl acetate (25
ml), dissolved in ammonium hydroxide (30%,
300 ml). The solution became clear and solution
was stirred at room temperature overnight. The
mixture was concentrated to dryness under
reduced pressure. The residue was treated with
methanol (150 ml) and the resulting mixture
was heated at 80oC for 1 hour, cooled, and
allowed to stand at room temperature overnight.
The resulting solid was collected by filtration
and recrystallized from water (1700 ml) using 1
gram of activated carbon. The filtrate was
cooled to room temperature, and stored in the
refrigerator overnight. The resulting solid was
collected by filtration, washed twice with
methanol (20 ml), and dried to give pure
acyclovir 1 (30 g, 63%). mp. 242 - 244oC (H2O).
UV λmax (MeOH-H2O; 1-1) nm: 251, 276 (sh);
1H-NMR (DMSO-d6, 500 MHz, δ ppm): δ 3.34,
3.46 (s, 4H, CH2CH2), 4.65 (br, 1H, OH), 5.34
(s, 2H, OCH2O), 6.48 (s 2H, NH2), 7.80 (s, 1H,
H-8), 10.62 (s, 1H, NH). EI-MS m/e (%) 226
[M+] (100), 152 [M+-C3H6O2] (42). The mother
liquor was concentrated to give a second crop
(2.6 g) which contained the N7-isomer.
Antiherpetic activity evaluation
a) Cells and viruses
Vero cells (Green Africa Monkey Kidney)
were propagated in culture medium (Medium
Essential Medium (MEM, GIBCO),
supplemented with 3% fetal bovine serum (FBS,
Sigma), glutamine, non-essential amino acid,
and antibiotics).
The 5 clinical HSV isolates used in this
study included 2 HSV-1 and 3 HSV-2.
b) Method of plaque reduction assay (PRA)
Confluent Vero cell monolayer in 24-well
culture plates were infected with 200 μl of 10
fold dilutions from 10-5 to 10-2 of virus stocks
per well. After 1 hour incubation at 37oC x
5%CO2 with gently rocking, inoculates were
discarded and cells were incubated with culture
medium and 1.0% methylcellulose (Sigma) with
the presence of increasing antiviral
concentrations of 0, 1, 5, 15, and 50 μM.
Plaques were counted at 72 h post inoculation
after cells were treated with formaldehyde and
stained with crystal violet. IC50s were
determined on log papers and defined as the
minimum concentration of ACV that reduced
the numbers of plaque by 50% compared to the
cell controls (absence of ACV). IC50s ≥ 7 μM
were considered resistant to ACV.
III - Results and discussion
1. Preparation of acyclovir
A method for the preparation of ACV is
526
provided that is suitable for the commercial
manufacture of the product. In the first step,
guanine is acetylated using acetic anhydride,
acetic acid, and phosphoric acid. In the second
step, diacetyl guanine is alkylated at the N9-
position using CH3COOCH2O(CH2)2OCOCH3,
acetic anhydride and phosphoric acid or
polyphosphoric acid. The acetyl groups are then
removed as desired.
IC50
Figure 4: Plot for determination of IC50
2. Acetylation of guanine
In the first step of the reaction, the 2-amino
group of guanine is protected to prevent it from
being alkylated in the second step of the
reaction. The choice of protecting group may
effect the ultimate yield of product, in that
protecting groups are removed with varying
degrees of difficulty. In general, in the process
of protecting the 2-amino group, the N9 group
usually also reacts with the protecting group.
Acylation, and in particular, acetylation,
activates the N9-position toward alkylation in
the second step, and therefore, is desirable.
Diacetylguanine, which has been used as an
intermediate in the production of acyclovir, has
been prepared using several methods. Guanine
has been acetylated using acetic anhydride in
N,N-dimethylacetamide to give diacetylguanine
in 90.5% yield [6]. This reaction produces a
product which is grey in color due to the high
reaction temperature used (160oC for 7 hours).
In general, it is preferred to use a symmetrical
anhydride in the reaction scheme that
corresponds to the acid used. For example,
acetic acid is preferably used in combination
with acetic anhydride, and propionic acid is
preferably used in combination with propionic
anhydride.
Guanine has also been acetylated in acetic
anhydride and acetic acid to give different
products depending on the work-up conditions
[7]. For example, after the reaction mixture
becomes an almost clear solution, if solvents are
removed by distillation, only diacetyl guanine is
obtained in 95% yield. However, the addition of
water at 60oC. followed by stirring at room
temperature overnight produces N2-
acetylguanine in 94.4% yield. If the reaction
mixture is merely cooled down, a mixture of
mono- and di-acetylguanine is produced.
3. Preparation of dioxolane-diacetate (7)
The dioxolane ring is opened using acetic
anhydride as the ring-opening reagent in the
presence of catalytic amounts of p-
toluenesulfonic acid. This provided dioxolane-
diacetate in 80% yield after distillation by the
method of Chen et al. [8].
4. Alkylation of diacetylguanine
In this step of the synthesis, the diacetylated
guanine from previous step is alkylated in the
N9-position to produce 2-acetamido-9-(2-
acetylethoxymethyl)guanine.
Matsumoto, et al., have studied the effect of
solvent, acid catalyst and reaction temperature
on the yield of the alkylation of diacetylguanine
with 2-oxo-1,4-butanediol diacetate ("dioxolane
diacetate") to produce N2 ,O-diacetylacyclovir
[7]. Among the acid catalysts tested (p-
toluenesulfonic acid, sulfanilic acid, p-
nitrobenzenesulfonic acid, 2,4-dinitrobenzene
sulfonic acid, iron(II) sulfate, and zinc chloride),
Matsumoto reported that p-toluenesulfonic acid
and sulfanilic acid exhibited the highest
catalytic activity. In a preferred reaction
scheme, a combination of an acid and anhydride
are used.
5. Deacetylation of acyclovir diacetate
Both methylamine and ammonium
hydroxide proved to be good deacetylating
agents. Although the working-up is easier using
methylamine than it is using ammonium
hydroxide, on an industrial scale, the smell of
methylamine may dictate the preferred use of
ammonium hydroxide as a deacetylation agent.
527
The synthesized ACV has been analyzed in
the National Institute for Drug Quality Control.
It meets all the standards of BP 2007.
6. Biological activity
ACV was evaluated against HSV-1 and HSV-
2. The effects of standard ACV and tested ACV
on 5 clinical HSV isolates included HSV-1 and
HSV-2 were tested in parallel with their antiviral
activity. The results are given in table 1.
Table 1: The antiviral activity of ACV compared to the standard ACV
IC50
Order
Clinical HSV
isolate Type Standard Tested
Correlated
coefficient
1 06003 HSV-2 1.70 S 1.20 S
2 07069 HSV-1 0.53 S 0.57 S
3 07089 HSV-2 0.91 S 0.10 S
4 07092 HSV-2 2.80 S 2.60 S
5 07094 HSV-1 0.89 S 0.53 S
0.95
S: Sensitive.
.
The tested ACV showed the anti-HSV
activity at low concentration and very
corresponds with standard ACV. The correlated
factor is 0.95.
‘
Figure 5: Antiherpestic activity of standard
(left) and tested (right) acyclovir
IV - Conclusion
This report describes a one-pot process for
the preparation of acyclovir from guanine.
Reacting N2,N9-diprotected guanine with 1-
acetyl-2-acetylmethoxy-ethyleneglycol in
present of phosphoric acid as catalyst provide
ACV with high yield and good regioselectivity.
Therefore, the purification was simple,
inexpensive and conforming to pilot scale. The
chemicals and the solvents were common and
friendly with environment. The antiherpetic
activity of the synthesized ACV was show to be
comparable (95%) to the standard ACV. This
synthesized ACV was approved by National
Institute of Drug Quality Control to meet the
quality standard of BP 2007.
Acknowledgements: This research was
supported by a research grant from Vietnam
Academy of Science and Technology (VAST).
References
1. H. J. Schaeffer, L. Beauchamp, P. Miranda
de, G. B. Elion, D. J. Bauer, P. Collins.
Nature, 272, 583 - 585 (1978).
2. Thuong Nguyen Thi. Master of Medicine
dissertation, 2006, National Institute of
Hygiene and Epidemiology.
3. Balfour HH Jr. N. Engl. J. Med., 340, 1255
- 1268 (1999).
4. J. C. Martin, C. A. Dvorak, D. F. Smee, T.
R. Matthews, J. P. Verheyden. J. Med.
Chem., 26(5), 759 - 761 (1983).
5. Hongwu Gao, Ashim K. Mitra. Synthesis, 3,
329 - 351 (2000).
6. R. Zou and M. J. Robins. Can. J. Chem., 65,
1436 - 1437 (1987).
528
7. H. Matsumoto, C. Kaneko, K. Yamada, T.
Takeuchi, T. Mori, Y. Mizuno. Chem.
Pharm. Bull. 36 (3), 1153 - 1157 (1988).
8. Z. J. Chen, W. G. Liu, J. Z. Song, Y. Zhang.
Chemical Abstracts, 117, 1992, 151269e.
9. Smith J. B. CaractÐrisation des mutaion du
virus herpÌs simplex impliquÐes dans la
résistance aux antiviraux. ThÌse de
Philosophie Doctor (Ph.D.), 2004, FacultÐ
de médecine. UniversitÐ Laval QuÐbeque.
Corresponding author: Tran Van Sung
Laboratory of Organic Synthesis, Institute of Chemistry, VAST.
Các file đính kèm theo tài liệu này:
- 4633_16616_1_pb_7653_2085251.pdf